Background Image
Table of Contents Table of Contents
Previous Page  115 / 88 Next Page
Basic version Information
Show Menu
Previous Page 115 / 88 Next Page
Page Background

115

CASO CLÍNICO

Actualidad

Médica

A C T U A L I D A D

M É D I C A

www.actualidadmedica.es

©2016.Actual.Med.Todoslosderechosreservados

DOI: 10.15568/am.2016.798.cc03

Actual. Med.

2016; 101: (798): 115-116

Bilateral jaw fracture after long term treatment

with bisphosphonates. A case report.

Abstract

Bisphosphonates represent type of medication used for treating numerous pathologies. In fact, more and more

clinicians utilize bisphosphonates for dealing oncological diseases, rheumatic pathologies and severe osteoporosis.

Despite its benefits, various undesirable side effects have also been associated with the use of these drugs. For

instance, patients who receive bisphosphonates present a greater risk of suffering osteonecrosis of jaw. Indeed,

the possibility of experiencing this complication is around 0,812% when bisphosphonates are administered

intravenously. In contrast, the risk is about 0,01% with oral administration. However, when a tooth extraction is

carried out the risk rises to 0,34%. This report presents the case of a 66 years old woman who suffered a bilateral

jaw fracture after prolonged treatment with bisphosphonates. Interestingly, no invasive dental procedures were

referred by patient. The main aim of this paper is to focus the attention on the serious complications that this

treatment may show in the long term.

Resumen

Los bifosfonatos son fármacos ampliamente utilizados en el tratamiento de numerosas enfermedades. Diferentes

profesionales utilizan los bifosfonatos para tratar complicaciones de patologías oncológicas, osteoporosis y pato-

logías reumatológicas. Sin embargo, a pesar de los efectos benéficos, existen efectos secundarios consecuente al

utilizo de este tipo de medicamento. Por ejemplo, la osteonecrosis maxilar es más frecuente en pacientes trata-

dos con bifosfonatos. En este sentido, la posibilidad de desarrollar osteonecrosis maxilar es del 0,812% cuando la

medicación es administrada por vía intravenosa y del 0,01% en caso de administración oral. Además, cuando se

realiza una extracción dental el riesgo incrementa de un 0,34%. Este artículo presenta el caso de una paciente de

66 años que sufrió una fractura bilateral y espontanea de la mandíbula tras el utilizo de bifosfonatos durante un

largo periodo de tiempo. Es importante enfatizar que, en este caso, el paciente no había sido sometido a inter-

venciones de cirugía oral en los meses previos. El principal objetivo de este estudio es focalizar la atención sobre

las posibles complicaciones provocadas por este medicamento.

Paolo Cariati

1

, Dario Sanchez Lopez

2

, Miguel Perez de Perceval

1

, Alfredo Valencia

2

,

Blas Gracia Medina

2

1

Residente de Cirugía Oral y Maxilofacial. Complejo Hospitalario Granada.

2

FEA Cirugía Oral y Maxilofacial. Complejo Hospitalario Granada.

Paolo Cariati

ComplejoHospitalariodeGranada

Email:

paolocariati1@gmail.com

Palabras clave: Fractura

de mandibula bilateral,

bifosfonatos, hueso

mandibular, osteonecrosis

maxilar

Keywords: Bilateral jaw

fracture, bisphosphonates, jaw

bone, ONJ

Fractura bilateral demandibular tras un tratamiento a largoplazo

conbifosfonatos

INTRODUCTION:

Several studies demonstrated that Bisphosphonates are an

important and well-established drug in the treatment of several

diseases (1). Its represent the first-line treatment for malignant hy-

percalcemia and bone metastasis (2). Moreover, bisphosphonates

are also used for treatment of paget’s disease, osteoporosis, and

multiple myeloma (3). When administered, bisphosphonates are

deposited into the bones, due to high affinity for hydroxyapatite,

and are accumulated through time (4). It is common knowledge

that patients who receive these medicines have an increased risk

of suffering ONJ (5) (6). This risk is around 0,812% if bisphosphona-

tes are administered intravenously. Whereas, is less for oral admi-

nistration (0,01%). Notwithstanding, the risk rises to 0,34% when

invasive dental procedures are performed in patients treated with

this drugs (4).In this sense, professionals who prescribe bisphos-

phonates must strongly advise about this complication and dental

extractions should be avoided in these case (7) (8) (9).

CASE REPORTS:

We describe the case of a 66-year-old woman who came to

the emergency service of our Hospital with mouth pain, active oral

suppuration, fever and bad general condition. Once in the hospital,

Enviado:23-05-2016

Revisado: 13-06-2016

Aceptado: 18-08-2016